Quarterly ResultMay 11, 2026, 07:41 AM
Intellia Therapeutics Reports Positive Lonvo-z Phase 3 Data, Initiates BLA; Q1 Net Loss $96.2M
AI Summary
Intellia Therapeutics announced its first quarter 2026 financial results and significant business updates. The company reported positive topline Phase 3 HAELO clinical data for lonvo-z in Hereditary Angioedema (HAE), showing an 87% reduction in attacks, and initiated a rolling Biologics License Application (BLA) submission to the FDA, targeting a U.S. launch in the first half of 2027. Additionally, patient screening resumed for the Phase 3 MAGNITUDE and MAGNITUDE-2 clinical trials of nex-z in ATTR amyloidosis. For Q1 2026, Intellia reported a net loss of $96.2 million, an improvement from $114.3 million in Q1 2025, and strengthened its balance sheet with an April public offering, extending its cash runway into 2028.
Key Highlights
- Lonvo-z Phase 3 HAELO trial reduced HAE attacks by 87% vs. placebo.
- 62% of lonvo-z patients were attack-free and therapy-free for six months.
- Rolling BLA submission initiated for lonvo-z; U.S. launch anticipated H1 2027.
- Nex-z Phase 3 trials (MAGNITUDE, MAGNITUDE-2) resumed patient screening.
- Cash, cash equivalents, and marketable securities were $517.2M as of March 31, 2026.
- Underwritten public offering in April 2026 raised $207M gross proceeds.
- Q1 2026 net loss was $96.2M, down from $114.3M in Q1 2025.
- R&D expenses decreased to $80.7M in Q1 2026 from $108.4M in Q1 2025.